Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
6.00
0.00 (0.08%)
Sep 11, 2026, 4:00 PM EDT - Market closed
Adial Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
The acquisition brings a novel, colon-targeted therapy for ulcerative colitis and up to $64M in financing, with Azora equity holders gaining majority ownership. The combined company will focus on advancing AT177 through early clinical milestones.